Breadcrumb Home News Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer Source: Arvinas | Date: 05/04/2026 Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer Image Click here to view the full article Startups & Spinouts Faculty
